Safety

Prevenar 13® is generally well tolerated1

Infants and children aged 6 weeks to 5 years1
The most commonly reported adverse reactions in children 6 weeks to 5 years of age were vaccination-site reactions, fever, irritability, decreased appetite, and increased and/or decreased sleep. 

Children and adolescents aged 6 to 17 years of age1
The most common adverse events in children and adolescents 6 to 17 years of age were headaches, decreased appetite, vomiting, diarrhoea, rash, urticaria or urticaria-like rash, irritability, any vaccination-site erythema, induration/swelling or pain/tenderness, somnolence, poor quality sleep, vaccination-site tenderness (including impaired movement) and pyrexia. 

 

Reference

  1. Prevenar 13® Summary of Product Characteristics. November 2020



Legal Category: S1A

PP-PNA-IRL-0012  Preparation Date: March 2022